Videos

Expert perspective on CheckMate 9ER quality of life data and treatment implications for patients with advanced RCC.

Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.

Reflection on biomarkers, treatment resistance, and other unmet needs in 1L treatment of advanced RCC by Rana R. McKay, MD.

Dr Rana McKay provides insight on preferred therapeutic options for first-line treatment of RCC and how patient risk stratification influences decision making.

Rana R. McKay, MD, reflects on the landscape of advanced RCC, discusses histology, subsets of kidney cancer, and IMDC criteria for prognostic stratification.

Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.

Before closing out their module on ESR1 mutation, panelists identify its impact on treatment options for patients diagnosed with HR+/HER2- metastatic breast cancer.

In the context of ESR1 mutation in HR+/HER2- metastatic breast cancer, key opinion leaders consider ideal testing modalities and timing to improve patient outcomes.

John Diaz, discusses key targets for cervical cancer and ovarian cancer.

Federico Albrecht, MD, comments on clinical trials supporting the use of PD-L1 inhibitor therapy in combination with standard chemotherapy for the treatment of patients with extensive-stage small cell lung cancer.

Andreas Varkaris, MD, PhD, discusses PIK3CA mutations in breast cancer and the novel therapies being developed to treat these tumors.

Andrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.

Samer A. Srour, MD, MS, discusses what challenges need to be faced when moving forward with the phase 1 trial of Orca-Q in patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.

Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.

Key takeaways from recent data updates from the PRIMA and PAOLA-1 trials investigating PARP inhibitors in ovarian cancer.

Chad A. Hamilton, MD, shares strategies for managing gastrointestinal toxicities and fatigue for patients receiving PARP inhibitors for the treatment of ovarian cancer.

Clinical insights on adverse effects seen with PARP inhibitors in the treatment of patients with ovarian cancer.

An overview of factors that influence the initiation of maintenance therapy for patients with ovarian cancer.

Chad A. Hamilton, MD, discusses how clinical trial data inform treatment selection for patients with ovarian cancer.

A comprehensive overview of the maintenance therapy landscape in ovarian cancer, with a focus on clinical trials investigating bevacizumab, olaparib, and niraparib.

An expert gynecologic oncologist reviews guideline recommendations for molecular testing in ovarian cancer and shares his testing practices.

Chad A. Hamilton, MD, presents the case of a 49-year-old woman with BRCA wild-type ovarian cancer and offers his initial impressions.

Nathan Bahary, MD, PhD, discusses the ongoing challenge of chemotherapy drug shortages in the oncology field.

Everett E. Vokes, MD, discusses the clinical application of next-generation sequencing for head and neck cancers, including thyroid cancers.

Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.

Raajit K. Rampal, MD, PhD, discusses the evolution of treatments for patients with myelofibrosis, and notes what he is excited to see more of in the future.

Nicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.

Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.

Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.

Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.